Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Frequency Therapeutics Inc (KRRO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: KRRO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -91.17% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 149.75M USD | Price to earnings Ratio - | 1Y Target Price 138.66 |
Price to earnings Ratio - | 1Y Target Price 138.66 | ||
Volume (30-day avg) 84642 | Beta - | 52 Weeks Range 15.16 - 98.00 | Updated Date 04/2/2025 |
52 Weeks Range 15.16 - 98.00 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -9.37 |
Earnings Date
Report Date 2025-03-24 | When Before Market | Estimate -2.5129 | Actual -2.26 |
Profitability
Profit Margin - | Operating Margin (TTM) -1014.53% |
Management Effectiveness
Return on Assets (TTM) -25.65% | Return on Equity (TTM) -50.61% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 68422986 | Price to Sales(TTM) 65.94 |
Enterprise Value 68422986 | Price to Sales(TTM) 65.94 | ||
Enterprise Value to Revenue 30.13 | Enterprise Value to EBITDA -5.6 | Shares Outstanding 9388900 | Shares Floating 4913494 |
Shares Outstanding 9388900 | Shares Floating 4913494 | ||
Percent Insiders 6.42 | Percent Institutions 101.67 |
Analyst Ratings
Rating 4.43 | Target Price 137.76 | Buy 4 | Strong Buy 3 |
Buy 4 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Frequency Therapeutics Inc
Company Overview
History and Background
Frequency Therapeutics, Inc. (FREQ) was founded in 2014 and is a biotechnology company focused on developing therapeutics for hearing loss. They are pioneering a new approach to treating hearing loss by using progenitor cell activation (PCA) to regenerate hair cells within the inner ear.
Core Business Areas
- Hearing Loss Therapeutics: The company's primary focus is on developing and commercializing therapeutics for acquired sensorineural hearing loss (SNHL), a common type of hearing loss.
Leadership and Structure
David L. Lucchino serves as the Chief Executive Officer. The company has a board of directors overseeing its operations and a management team responsible for executing its strategy.
Top Products and Market Share
Key Offerings
- FX-322: FX-322 is Frequency Therapeutics' lead product candidate, an investigational, locally administered potential disease modifying therapeutic for the treatment of acquired SNHL. It is currently in clinical trials. While no current market share or revenue data is available as the product is not yet approved, competitors include companies developing hearing aids, cochlear implants, and gene therapies such as Decibel Therapeutics (DBTX).
Market Dynamics
Industry Overview
The hearing loss therapeutics market is large and growing, driven by an aging population, noise exposure, and ototoxic medications. Current treatments are primarily assistive devices like hearing aids and cochlear implants, creating a significant unmet need for disease-modifying therapies.
Positioning
Frequency Therapeutics is positioned as an innovator in the field of hearing loss, utilizing a novel PCA approach to potentially regenerate hair cells and restore hearing function. Their competitive advantage lies in their unique technology and potential to address the underlying cause of hearing loss.
Total Addressable Market (TAM)
The global hearing loss market is estimated to be in the billions of dollars. Frequency Therapeutics, if successful, could capture a significant portion of this market by offering a disease-modifying therapy.
Upturn SWOT Analysis
Strengths
- Novel PCA technology platform
- Potential to address unmet need in hearing loss treatment
- Experienced management team
- Strong intellectual property position
Weaknesses
- Reliance on a single lead product candidate (FX-322)
- High clinical trial risk and significant capital expenditure required
- Limited financial resources
Opportunities
- Positive clinical trial results for FX-322
- Partnerships with larger pharmaceutical companies
- Expansion of PCA platform to other therapeutic areas
Threats
- Failure or delay in clinical trials
- Competition from other companies developing hearing loss therapies
- Regulatory hurdles and approval delays
- Difficulty raising capital
Competitors and Market Share
Key Competitors
- DBTX
- SONX
- AKOU
Competitive Landscape
Frequency Therapeutics faces intense competition from other biotechnology and pharmaceutical companies developing hearing loss therapies. Success hinges on demonstrating clinical efficacy and safety and gaining regulatory approval.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the company being in the development stage.
Future Projections: Future growth depends on the successful clinical development and commercialization of FX-322. Analyst estimates vary widely due to the uncertainty surrounding the clinical trial outcomes.
Recent Initiatives: Recent initiatives include advancing FX-322 through clinical trials.
Summary
Frequency Therapeutics is a high-risk, high-reward biotechnology company focused on a novel approach to hearing loss treatment. The company's success hinges on the positive results of its clinical trials for FX-322. Failure to demonstrate efficacy or safety could result in significant losses for investors. However, if successful, the company could capture a significant share of the multi-billion dollar hearing loss market.
Similar Companies
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- ClinicalTrials.gov
- Financial News Outlets
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise. Clinical trial outcomes are uncertain, and future performance is not guaranteed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Frequency Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2023-11-06 | CEO, President, Interim Principal Financial Officer & Director Dr. Ram Aiyar MBA, Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 104 | Website https://www.korrobio.com |
Full time employees 104 | Website https://www.korrobio.com | ||
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. Its lead product candidate is KRRO-110 which is in Phase 1/2 clinical trial for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.